Magnetic resonance imaging

Enhancing Prostate Cancer Screening: AI, Imaging and Clinical Innovations, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Algorithm, MRI, Prostate cancer, Radiology, Medical imaging, Magnetic resonance imaging, Partnership, Prostate-specific antigen, PET, Bachelor of Science, Artificial intelligence, AI, Doctor of Philosophy, MBBS, University College London, Workforce, PSA

TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests. The featured speakers will also discuss the critical role artificial intelligence (AI) will play in combination with clinical and imaging tests to deliver sustainable, patient-centric screening pathways.

Key Points: 
  • In this free webinar, learn about the evolution of prostate cancer screening and the shift to magnetic resonance imaging (MRI)-based diagnostic tools for more accurate screening.
  • The featured speakers will share insights into the development of AI-based algorithms in prostate cancer, including best practices and pitfalls.
  • The speakers will also discuss ongoing clinical studies shaping the future of prostate cancer detection and treatment.
  • TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests.

Summary of opinion: Bimzelx, 21/03/2024 Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Psoriatic arthritis, Hidradenitis suppurativa, Methotrexate, Psoriasis, MRI, Magnetic resonance imaging, Inflammation, Committee, Nonsteroidal anti-inflammatory drug, Disease-modifying antirheumatic drug, HS, Medication package insert, C-reactive protein, Ankylosing spondylitis, European Commission, Marketing, CHMP, CRP, Axial spondyloarthritis

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bimzelx.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bimzelx.
  • The marketing authorisation holder for this medicinal product is UCB Pharma S.A.
  • The CHMP adopted a new indication for the treatment of hidradenitis suppurativa.
  • Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
    Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Privacy and the Rise of “Neurorights” in Latin America

Retrieved on: 
Tuesday, April 2, 2024
Algorithm, LGPD, Artificial intelligence, Parliament, Constitution, Neuroprivacy, Spanish, Rise, Emotion, EEG, Civil code, Congress, MRI, Initiative, BRAIN, Emotiv, Policy, Initialization (programming), UNESCO, Ferhat Ozcep, OECD, Brazilian, Supreme court, Confidentiality, Safety, Language, Latin American Parliament, Senate, State, Rapporteur, Digital, Magnetic resonance imaging, Constitution of Brazil, Research, Peripheral nervous system, AI, Economy, RIPD, Health, Brain, Network, Trust, Record, Organization, Spinal cord, Traction, Electroencephalography, Court

Authors: Beth Do, Maria Badillo, Randy Cantz, Jameson Spivack “Neurorights,” a set of proposed rights that specifically protect mental freedom and privacy, have captured the interest of many governments, scholars, and advocates. Nowhere is that more apparent than in Latin America, where several countries are actively seeking to enshrine these rights in law, and some [?]

Key Points: 


Authors: Beth Do, Maria Badillo, Randy Cantz, Jameson Spivack “Neurorights,” a set of proposed rights that specifically protect mental freedom and privacy, have captured the interest of many governments, scholars, and advocates. Nowhere is that more apparent than in Latin America, where several countries are actively seeking to enshrine these rights in law, and some [?]

EQS-News: Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Janus, Psoriasis, Research, Webcast, German, MRI, General assembly, Biotechnology, Calcium, Expense, Regeneration, Capital punishment, SIRT6, Conference, Biomarker, AFL, Patent, PMS, Histology, Clinical trial, Investment, Ulcerative colitis, Magnetic resonance imaging, SPMS, Research and development, Multiple sclerosis, UC, Administration, Patient, Disease, RMS, Pharmaceutical industry

The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).

Key Points: 
  • The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).
  • The results demonstrated meaningful improvements over placebo in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024
Research, ARIA, FLNA, Drug development, ADAS, Exercise, ADAS-Cog, Private law, Mass spectrometry, Criterion, CDR, Bawskee 3.5, Protein, Intellectual property, Patient, Plasma, Cassava Sciences, PET, MRI, City University, Hyperkinesia, Cerebrospinal fluid, Edema, Cassava, Memory, Insulin, G&A, Tablet, Brain, City, CUNY, SAP, Calendar, Completion, Safety, Clinical, Knowledge, Alzheimer's disease, Magnetic resonance imaging, Blood, FDA, Ageing, Food, Data, Lymphocyte, Medicine, DSMB, Pharmaceutical industry

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.

Alberta Innovates Provides $12.4 million to Advance Health Innovations

Retrieved on: 
Monday, February 26, 2024
Robotics, Emergency, AICE, University, Alberta Innovates, Injury, POCUS, Health, DSM-IV codes, Magnetic resonance imaging, Patient, Dentistry, Infection, Faculty, Brain, Pharmaceutical industry

Dr. Abhilash Hareendranathan, from the Faculty of Medicine and Dentistry at the University of Alberta, is a recipient of an Accelerating Innovations into Care (AICE)-Concepts award from Alberta Innovates , and believes he has an answer to that question.

Key Points: 
  • Dr. Abhilash Hareendranathan, from the Faculty of Medicine and Dentistry at the University of Alberta, is a recipient of an Accelerating Innovations into Care (AICE)-Concepts award from Alberta Innovates , and believes he has an answer to that question.
  • This unique opportunity is part of the suite of AICE programs designed to advance health technologies toward market adoption with the aim of providing positive economic and health impacts for Alberta.
  • This year, 10 awards are being provided to researchers and innovators around Alberta for a total of $6.1 million.
  • We’re grateful that Alberta Innovates supports our researchers’ efforts to get their life-changing innovations from the lab to the bedside, to help improve outcomes for patients in Alberta and beyond.

Study: Prenatal COVID exposure associated with changes in newborn brain

Retrieved on: 
Thursday, February 22, 2024
Cortex, Paper, Oxygen, Anxiety, Nursing, Infection, Coronavirus, Magnetic resonance imaging, Inflammation, Neuron, Fetus, Schizophrenia, Hospital, Pregnancy, Learning, Life, Radiation, Risk, Human, COVID-19, Frontal lobe, Walking, Virus, Health, Mother, COVID, Infant, Patient, Depression, Attention deficit hyperactivity disorder, News, Child, Fungal infection, Spectrum, Placenta, Research, MRI, Brain, Medical imaging

The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development, said Nickie Andescavage, M.D.

Key Points: 
  • The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development, said Nickie Andescavage, M.D.
  • In contrast, an inner area of the brain, known as deep gray matter, was smaller than in unexposed babies.
  • “Their brains formed differently if they were exposed to COVID,” said Dr. Andescavage, adding that “those exposed to COVID had unique signatures” in the brain.
  • But other studies have linked maternal stress and depression to changes in the newborn brain .

Introduction of Breast Imaging Legislation Will Benefit Thousands of Kansans

Retrieved on: 
Thursday, March 7, 2024
Breast cancer, Overland Park, Kansas, Woman, Breast MRI, Biopsy, Life, Health, Magnetic resonance imaging, House, Patient, Google Images, Disease, MRI, Medical imaging

TOPEKA, Kan., March 7, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, commends Representative Linda Featherston (D-Overland Park) and Representative Laura Williams (R-Lenexa) for working with Komen to eliminate financial barriers to earlier breast cancer detection by ensuring that everyone has equitable access to diagnostic and supplemental breast imaging.

Key Points: 
  • In Kansas, more than 2,600 people will be diagnosed with breast cancer and 370 are expected to die of the disease in 2024 alone.
  • HB 2689 , introduced by Reps. Featherston and Williams, eliminates the patient out-of-pocket costs for medically necessary diagnostic and supplemental breast imaging including MRIs, ultrasounds, and diagnostic mammograms.
  • An estimated 12% of individuals are called back for additional imaging after an abnormal screening mammogram and require diagnostic imaging.
  • This diagnostic or supplemental imaging is often crucial for individuals previously diagnosed with breast cancer or those considered high-risk.

WELL's OceanMD Experiences Significant User Growth and Announces Upcoming Launch of New 'Health Messenger' to Help Care Providers Communicate Securely and Efficiently

Retrieved on: 
Thursday, March 7, 2024
Online, Diagnosis, Clinical decision support system, Magnetic resonance, Hospital, Caregiver, Intelligence, Messenger, TSX, Secure messaging, FHIR, Growth, Surgeon, Calendar, Entrepreneurship, SMS, Communication, Public sector, Magnetic resonance imaging, Yoy, WELL, API, Health, Medical imaging, Patient, EConsult, MRI, Nursing

This represents 78% YoY growth in total sites and 65% YoY growth in active users.

Key Points: 
  • This represents 78% YoY growth in total sites and 65% YoY growth in active users.
  • User engagement on the Ocean Platform has increased substantially with more than 2 million patient engagements3 every month reflecting 67% growth YoY.
  • OceanMD announces the upcoming launch in Q2-2024 of its mobile-first Health Messenger product which will help improve and secure communications between healthcare providers and their patients.
  • In 2023, OceanMD demonstrated robust growth across multiple dimensions, including clinic and site expansions, user base increases, and provider engagement.

Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients

Retrieved on: 
Friday, March 1, 2024
MRI, Acquisition, CE, White matter, Myenteric plexus, 2D, AI, Traumatic brain injury, Magnetic resonance imaging, FDA, Synthetic, Cerebrospinal fluid, 3D, Neurodegenerative disease, TBI, Radiology, Multiple sclerosis, DSM-IV codes, PHG, Quant, Health, Patient, Dementia, Diagnosis, Software, AEX, Brain, Medical imaging

As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Key Points: 
  • As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
  • Philips' exclusive agreement with SyntheticMR makes it the only company currently able to offer SyMRI NEURO 3D capability on MR scanners.
  • Accurate measurement of the volume and distribution of different tissue types in the brain is important for diagnosing brain disease.
  • "Smart Quant allows for shorter exams and exploration of quantitative metrics, which show great potential to better stratify patients with similar imaging characteristics on conventional MR sequences.